News // 21 October 2018
IntegraGen presents new data expanding application of miR-31 to stage III colon cancer during ESMO 2018

Analysis of PETACC-8 clinical trial samples demonstrates company’s proprietary miR-31 microRNA biomarkers identifies subpopulations of patients with resected stage III colon cancer who benefit from the addition of cetuximab to FOLFOX adjuvant therapy
IntegraGen announced today that it presented data on the company’s proprietary miR-31 (…) »